Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4002474 | American Journal of Ophthalmology | 2013 | 9 Pages |
Abstract
BSRC patients with active disease naïve to systemic therapy have elevated serum levels of 3 key immune mediators known to promote T helper 17 (Th17) cells in autoimmune disease. Our results suggest that IL-21, IL-23, and TGF-β1 may play an important role in the development of site-specific Th17 cell-mediated inflammation in BSRC, which underscore the importance of systemic therapy and offer new insights into the potential of targeted treatments.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Paul Yang, C. Stephen Foster,